MDACC Study No:2013-0977 ( NCT No: NCT01998828)
Title:A Phase 2, Open-label, Randomized Study to Evaluate the
Safety and Efficacy of Momelotinib in Subjects with
Polycythemia Vera or Essential Thrombocythemia
Principal Investigator:Srdan Verstovsek
Treatment Agent:Momelotinib
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if momelotinib (MMB) can
help to control PV and/or ET. The safety of this drug will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Leukemia; Myeloproliferative Diseases
Phase of Study:Phase II
Treatment Agents:Momelotinib
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Gilead Sciences
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Srdan Verstovsek
For Clinical Trial Enrollment:713-792-7305
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults